A Science and Technology Blog
The world’s first human challenge trial for a vaccine against SARS-CoV-2 is set to begin in London in January. Human challenge trials for the SARS-CoV-2 virus have many challenges, including producing a strain that is less virulent, but Dr. Gagandeep Kang says such trials can provide information and help design better vaccines than we can do now with conventional trials.
Universal mask wearing decreases the chance of infection and, if infected, decreases the amount of virus particles (inoculum) a mask-wearer is exposed to thus causing only asymptomatic infection or mild COVID-19 disease.
A group of 16 scientists has written an open letter to Dr Richard Horton, editor of The Lancet and authors of the Russia’s Sputnik V novel coronavirus vaccine trial paper,…
Russia’s Sputnik V vaccines for novel coronavirus have been found to be safe for a period of 42 days and capable of inducing antibody responses in all the 42 participants…
A new vaccine candidate construct using chimpanzee adenovirus carrying the full length of novel coronavirus spike protein is able to achieve sterilizing immunity and prevent both upper and lower respiratory…
Interim results of Phase-1 and Phase-2 trials of an inactivated SARS-CoV-2 vaccine carried out in China show that the vaccine is well tolerated, safe, and produced neutralizing antibodies at 14…
Russia registering a vaccine for novel coronavirus even before beginning a Phase-3 trial and promising to begin full-scale production of the vaccine in September to make it available by November…
The presence of pre-existing T cell memory against four common cold coronaviruses which cross-reacts with novel coronavirus may not prevent SARS-CoV-2 infection, but at most be able to reduce the…
